News MedTech Barcelona
Stay informed with the latest insights, research, and developments
We’re excited to unveil the new website of MedTech Barcelona — a platform that not only showcases a renewed visual identity but also reflects our broader mission and international outlook. As of October 2024, the company officially transitioned into MedTech Barcelona, a Leitat-owned biotech company dedicated to innovation in the
Lourdes has been part of the core of MedTech Barcelona (formerly ReadyCell) for many years, leading the R&D team with intelligence, calm, and unwavering commitment. Her scientific vision, methodical approach, and deep expertise have left a lasting mark on the way we work and think.
This year, we had the privilege of celebrating 20 years of dedication from four of our esteemed colleagues—Sheila Guisado, Lourdes Gombau, Alberto Corcho, and Marta Corvo.
We inform you that as of October 2024, Leitat, through its proprietary company MedTech Innovation on Advanced Medicine S.L.U. (MedTech Barcelona), has successfully acquired ReadyCell S.L.’s branch of activity as well as all employees dedicated to the development and commercialization of the ready-to-use cell-based plates for in vitro ADME-Tox and
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) launched a draft on Drug Interaction Studies regulatory, the ICH M12. The aim of this document, preceded by the FDA's 2020 guideline, is to create a standardized reference which can be used around the globe.
